Home › Funds › Defilade Capital Management, L.P. › ASND

Defilade Capital Management, L.P. position in ASND

ASCENDIS PHARMA A/S · Health Care

Defilade Capital Management, L.P. reported holding 128,858 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$29.4M, representing 4.90% of its reported portfolio and ranking #8 among its reported holdings. Defilade Capital Management, L.P. has disclosed ASND holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)128.86K sh
Reported value held$29.36M
Portfolio Weight4.90%
First reportedQ4 2025
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Defilade Capital Management, L.P.'s ASND position evolved

Defilade Capital Management, L.P. first disclosed a stake in ASND in Q4 2025 at 85,694 shares (US$18.3M). The position peaked in Q3 2026 at 128,858 shares, worth US$29.4M. Across 4 filings, Defilade Capital Management, L.P. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 128,858 shares valued at US$29.4M — an increase of 34,015 shares quarter over quarter.. Notable position changes include a 39% trim in Q1 2026 (shares rose 17% over the following quarter), a 83% increase in Q2 2026 (shares fell 15% over the following quarter), a 36% increase in Q3 2026 (shares rose 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 85.69K $18.27M New
Q1 2026 51.90K $11.87M Reduce
Q2 2026 94.84K $25.30M Add
Q3 2026 128.86K $29.36M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 36 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.34B), T. Rowe Price Investment Management, Inc. (US$1.87B), WESTFIELD CAPITAL MANAGEMENT CO LP (US$1.17B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has Defilade Capital Management, L.P. held ASND?

Defilade Capital Management, L.P. has disclosed ASND holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Defilade Capital Management, L.P.'s current position in ASND?

As of Q3 2026, Defilade Capital Management, L.P. holds 128.86K shares of ASND (ASCENDIS PHARMA A/S), valued at $29.36M, representing 4.90% of its reported portfolio and ranking #8.

Has Defilade Capital Management, L.P. been buying or selling ASND?

In the latest 13F filing (Q3 2026), Defilade Capital Management, L.P. increased its position in ASND. The position peaked in Q3 2026 at 128.86K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., WESTFIELD CAPITAL MANAGEMENT CO LP, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.